An Open-label, Phase I Clinical Trial of Autologous T Cells Transduced With NY-ESO-1 Antigen-specific High-affinity T Cell Receptors in NY-ESO-1-positive Patients With Advanced Solid Tumors
An Open-label, Phase I Clinical Trial of Autologous T Cells Transduced With NY-ESO-1 Antigen-specific High-affinity T Cell Receptors in NY-ESO-1-positive Patients With Advanced Solid Tumors is a PHASE1 clinical asset sponsored by Guangzhou FineImmune Biotechnology Co., LTD. in Sarcoma, Lung Cancers, Melanoma. SEO and diligence focus: Super1 TCR-T, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Sarcoma
Modality: protein therapy
Target: Super1 TCR-T
Sponsor: Guangzhou FineImmune Biotechnology Co., LTD.
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 28, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Super1 TCR-T
View original source fields
Condition raw: Sarcoma, Lung Cancers, Melanoma
Condition normalized: Sarcoma, Lung Cancers, Melanoma
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: Super1 TCR-T
Target normalized: Super1 TCR-T